SCYNEXIS, Inc. Proceeds from Debt, Net of Issuance Costs
SCYNEXIS, Inc. (SCYX) reported Proceeds from Debt, Net of Issuance Costs of $9.50 million for the 1-month period ending 2020-04-09, per its 10-K filed 2022-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2022-03-29
- 2020-04-09: Proceeds from Debt, Net of Issuance Costs 1 month $9.50M.
| Period end | Proceeds from Debt, Net of Issuance Costs 1 month |
|---|---|
| 2020-04-09 | $9.50M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |